Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
about
A plant-derived recombinant human glucocerebrosidase enzyme--a preclinical and phase I investigationEnzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)Therapeutic potential of intracerebroventricular replacement of modified human β-hexosaminidase B for GM2 gangliosidosisReview and evaluation of the methodological quality of the existing guidelines and recommendations for inherited neurometabolic disordersTherapies for the bone in mucopolysaccharidosesCNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VIA rapid and sensitive method for measuring N-acetylglucosaminidase activity in cultured cellsClinical and Genetic Characteristics of Romanian Patients with Mucopolysaccharidosis Type IICase report of treatment experience with idursulfase beta (Hunterase) in an adolescent patient with MPS II.Hunter disease eClinic: interactive, computer-assisted, problem-based approach to independent learning about a rare genetic disease.Characterization of the MPS I-H knock-in mouse reveals increased femoral biomechanical integrity with compromised material strength and altered bone geometryInsights into Hunter syndrome from the structure of iduronate-2-sulfataseGuidelines for diagnosis and treatment of Hunter Syndrome for clinicians in Latin America.Growth patterns and the use of growth hormone in the mucopolysaccharidoses.Impact of Enzyme Replacement Therapy and Hematopoietic Stem Cell Therapy on Growth in Patients with Hunter Syndrome.Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review.Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series.Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5 years.Correction of CNS defects in the MPSII mouse model via systemic enzyme replacement therapy.Newborn screening for hunter disease: a small-scale feasibility studyMucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment.Low bone mineral content and challenges in interpretation of dual-energy X-ray absorptiometry in children with mucopolysaccharidosis types I, II, and VI.Activities of daily living in patients with Hunter syndrome: impact of enzyme replacement therapy and hematopoietic stem cell transplantation.Cognitive, medical, and neuroimaging characteristics of attenuated mucopolysaccharidosis type II.Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein.Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey.Pharmacokinetics and bioavailability of a therapeutic enzyme (idursulfase) in cynomolgus monkeys after intrathecal and intravenous administration.Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome.Glycosaminoglycan storage disorders: a reviewDiagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study.Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease.Clinical utility gene card for: mucopolysaccharidosis type II.A rare case of mucopolysaccharidosis: hunter syndrome.β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.Deep Genotyping of the IDS Gene in Colombian Patients with Hunter Syndrome.Multimodal detection of GM2 and GM3 lipid species in the brain of mucopolysaccharidosis type II mouse by serial imaging mass spectrometry and immunohistochemistry.
P2860
Q21092136-B7A4B85D-FABD-445E-BF0E-B40D9AFB11CAQ24186164-7EBBE741-8EAE-4000-8D2B-318A8907E5ACQ24201176-D8244A34-8EA7-411B-BFBE-F477CB45F2A5Q24235224-DC28D36A-C46D-4C3E-975F-538B69E7D495Q24241548-5449A26F-684D-4189-9D99-EE599697C04EQ24597943-15ED7114-1A1A-4798-A52C-03809966B2E6Q26771677-628DB71E-3A12-48BD-A76C-BA9517048792Q26852308-0487DC15-DC94-4957-9846-5134C2201DC5Q27333793-3D9AAF0A-940B-4F35-859C-73B016D566B2Q28476636-8FFF0078-A475-4264-8321-3F4524BB2616Q28534395-76F6C297-451A-455A-86B3-7032133695F7Q33627495-D5DAFC65-CAA2-4A45-B408-39E89F00CCB2Q33690151-5D300CB4-F938-4A01-AD77-4ED99B21FCF5Q33727361-E69EB480-7559-4FE7-ABB9-9557BC5E34E5Q33800106-F8574835-D20D-4D42-A882-C91CF78806C4Q33804689-3E227681-7172-45A2-97AA-FA9DCC4CBD0FQ33890337-AD155889-AF9C-41D7-85ED-E1833F567322Q33918468-088BE7A5-6F88-4506-B6B7-DC2C5904AE2CQ33923815-CA69A055-5A57-43F7-A4FA-08AA13BB404DQ33930719-5B7B2F2F-C550-4141-BF13-3196EAA57337Q34152598-B98B047D-197B-4414-844E-808EAA8D7443Q34266971-198558AA-768A-4698-B4F6-B909A9AB2985Q34341167-AA1160D8-9691-41AC-827E-7DA521B07C46Q34422346-954FBE67-AAD1-4948-A9A6-B7A9CBBCB259Q34562817-C3075F36-C09B-4196-968B-82D93730DCA3Q34657166-6759DE40-C53B-4EB8-BD66-9660C0ACA3DBQ35034318-5E26796F-812F-4820-AE17-6A31EA5058D4Q35034355-76F847FB-AE3B-449B-A3E1-BE7597CEBB10Q35050847-75CEA5F7-1E8D-483F-8DC7-31AB9EED639FQ35128899-A124C7C9-856E-473E-893D-2BDCFADB676BQ35250761-5825AD64-476B-4141-AB1E-0952C40C6E7DQ35319254-22716689-05B6-4F48-9932-C7A685369CEBQ35367599-8B9EB93D-8FA8-4156-AEF1-E2B88A5B6908Q35532055-01A5D474-4EE8-4B45-9A1C-C39FB08FB267Q35571515-AA966136-9DF1-4579-AB0C-A472A7804CCEQ35603655-A5E97CCA-9F26-4535-8F13-7C2280C94485Q35622967-F997F2D6-5F96-46FD-997D-31883908F12FQ35690999-D0F76D46-BA2E-45AE-B557-C3F9321C5EB6Q35848742-1577C130-883C-467C-BA29-6785A297D0D5Q36200634-FCE68513-797D-48F1-81A9-58CE53C97C97
P2860
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Mucopolysaccharidosis type II ...... of enzyme replacement therapy
@ast
Mucopolysaccharidosis type II ...... of enzyme replacement therapy
@en
Mucopolysaccharidosis type II ...... of enzyme replacement therapy
@nl
type
label
Mucopolysaccharidosis type II ...... of enzyme replacement therapy
@ast
Mucopolysaccharidosis type II ...... of enzyme replacement therapy
@en
Mucopolysaccharidosis type II ...... of enzyme replacement therapy
@nl
prefLabel
Mucopolysaccharidosis type II ...... of enzyme replacement therapy
@ast
Mucopolysaccharidosis type II ...... of enzyme replacement therapy
@en
Mucopolysaccharidosis type II ...... of enzyme replacement therapy
@nl
P2093
P2860
P921
P3181
P1476
Mucopolysaccharidosis type II ...... of enzyme replacement therapy
@en
P2093
Allan Meldgaard Lund
Ans T Van der Ploeg
Gunilla Malm
J Edmond Wraith
Linda De Meirleir
Maurizio Scarpa
Michael Beck
Nathalie Guffon
Olaf A Bodamer
P2860
P2888
P304
P3181
P356
10.1007/S00431-007-0635-4
P407
P50
P577
2008-03-01T00:00:00Z
P5875
P6179
1013302451